Trajan Group Holdings (TRJ) Stock Overview
Develops, manufactures, and sells analytical and life science products and devices in Malaysia, Japan, Australia, New Zealand, the United States, Europe, the Middle East, Africa, and India. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
TRJ Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Trajan Group Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.78 |
| 52 Week High | AU$1.29 |
| 52 Week Low | AU$0.69 |
| Beta | 0.51 |
| 1 Month Change | -12.36% |
| 3 Month Change | 7.59% |
| 1 Year Change | -37.10% |
| 3 Year Change | -60.51% |
| 5 Year Change | n/a |
| Change since IPO | -60.80% |
Recent News & Updates
Recent updates
Shareholder Returns
| TRJ | AU Life Sciences | AU Market | |
|---|---|---|---|
| 7D | 5.4% | 4.9% | 2.3% |
| 1Y | -37.1% | -47.0% | 10.1% |
Return vs Industry: TRJ exceeded the Australian Life Sciences industry which returned -47% over the past year.
Return vs Market: TRJ underperformed the Australian Market which returned 10.1% over the past year.
Price Volatility
| TRJ volatility | |
|---|---|
| TRJ Average Weekly Movement | 8.4% |
| Life Sciences Industry Average Movement | 10.1% |
| Market Average Movement | 9.3% |
| 10% most volatile stocks in AU Market | 19.7% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: TRJ has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: TRJ's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 650 | Stephen Tomisich | www.trajanscimed.com |
Trajan Group Holdings Limited develops, manufactures, and sells analytical and life science products and devices in Malaysia, Japan, Australia, New Zealand, the United States, Europe, the Middle East, Africa, and India. The company offers analytical products, including syringes, GC columns and septa, inlet liners, rings, and tubing products; and sampling products, comprising septa, caps, liners, well plates and sealing mats, crimping tools, and micro sampling tools, as well as automation systems and consumables. It also provides pathology products, consisting of NBF containers, adhesive and frosted microscope slides, coverslips, microtome blades, biopsy pads, microscope slide storage trays/mailers, microscope slide and cassette storage boxes, histology wax plus, and tissue marking dyes and sets, and MiPlatform, a smartphone adapter; on-line and laboratory instruments and related parts and services; and miniaturized and portable instrumentation, as well as products and services related to microsampling.
Trajan Group Holdings Limited Fundamentals Summary
| TRJ fundamental statistics | |
|---|---|
| Market cap | AU$115.93m |
| Earnings (TTM) | -AU$4.46m |
| Revenue (TTM) | AU$166.46m |
Is TRJ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TRJ income statement (TTM) | |
|---|---|
| Revenue | AU$166.46m |
| Cost of Revenue | AU$106.20m |
| Gross Profit | AU$60.27m |
| Other Expenses | AU$64.73m |
| Earnings | -AU$4.46m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.029 |
| Gross Margin | 36.20% |
| Net Profit Margin | -2.68% |
| Debt/Equity Ratio | 39.2% |
How did TRJ perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/04 03:07 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Trajan Group Holdings Limited is covered by 3 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Martyn Jacobs | Bell Potter |
| Elyse Shapiro | Canaccord Genuity |
| Thomas Godfrey | Ord Minnett Limited |